The financing serves as a catalyst for Entera Bio's lead candidate, EB613, an oral PTH (1-34) tablet currently targeting osteoporosis treatment. By securing these funds, the company has fully backed its upcoming Phase 3 registrational studies. According to data from Arx Capital Markets, the deal also ranks as the ninth-largest PIPE transaction across all Israeli industries.
A global legal team from Greenberg Traurig steered the transaction. The effort was led by Miami-based Corporate Practice Co-Chair Drew M. Altman and Shareholder Sami B. Ghneim, with support from Associate Angel A. Marcial and Tel-Aviv Managing Shareholder Joey T. Shabot. This capital infusion arrives as the company shifts its focus toward late-stage clinical development.
Comments (0)
No comments yet. Be the first!